Events

Towards sustainability and healthy living with the use of AI and other digital solutions
FEB
Tue
04
08:30 - 13:00

This was 1 week ago

Location

Brussels

Permanent Representation of Lithuania to the European Union
Belliardstraat 41/43, 1040 Brussels
Programmes
Health Digital, Industry & Space Climate, Energy, Mobility AI, data & cloud Deployment: Best use of technologies

Attachments

There is 1 attachment connected to this article.

Attachments are only accessible for people with an account on the NCP Flanders website.

Sign in (if you already have an account) or sign up.

The Lithuanian RDI Liaison Office in Brussels (LINO) and Kaunas University of Technology (KTU) are organising an event to explore how research, AI, and digital technologies can address global challenges in sustainability and health. Highlights include discussions on AI-driven innovations, tools for early disease detection, and technologies supporting carbon-neutral living. A panel session will also provide practical insights on collaboration opportunities in European programmes, fostering impactful international partnerships.

Please find the event description and program attached for more details.

Registration is requested via this link.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.